Clinical Trials Logo
  1. Home
  2. Transthyretin Amyloidosis
  3. NCT01171859

Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis

Transthyretin Amyloidosis Clinical Trial

Official title:
A Single Center, Twelve-month, Open-label, Prospective Study Followed by a Six-month Withdrawal Period to Evaluate the Efficacy, Tolerability, Safety and Pharmacokinetics of Doxycycline in Combination With Tauroursodeoxycholic Acid in Transthyretin Amyloidosis

Clinical Trial Summary

This study is being conducted to explore the potential benefits of a twelve-month doxycycline (at the best tolerated dose of 200 mg/day) and tauroursodeoxycholic acid (750 mg/day) treatment on disease progression in patients affected by transthyretin amyloidosis, including: 1) patients not eligible for liver transplantation; 2) patients eligible for liver transplantation, as a "bridge" therapy between the time of diagnosis and surgery, with the aim of stabilizing the disease; 3) patients showing disease progression after liver transplantation performed since at least 1 year.

It is a phase II, therapeutic exploratory, two-part, 18-month, single centre, prospective study.

Part I is a 12-month, open label treatment period in which doxycycline (200 mg/day, continuously) and tauroursodeoxycholic acid (750 mg/day continuously) are administered to 40 consenting subjects with transthyretin amyloidosis. Part II is a withdrawal period in which subjects will be monitored for disease progression. During part I, subjects will be evaluated at baseline (study Day 0), and then after 3, 6, 9 and 12 months of doxycycline plus tauroursodeoxycholic acid treatment or at premature treatment discontinuation; during part II, they will be assessed at months 15 and 18. Monthly phone contacts and blood tests will be performed to monitor potential adverse events.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01171859
Study type Interventional
Source IRCCS Policlinico S. Matteo
Contact
Status Completed
Phase Phase 2
Start date July 2010
Completion date October 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT03190577 - Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology N/A
Completed NCT03588468 - Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study N/A
Completed NCT03591757 - Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) Early Phase 1
Completed NCT05075798 - Study of Cerebral MRI Anomalies in Mutated Transthyretin Amyloidosis Patients
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Terminated NCT04611204 - Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release Surgery
Recruiting NCT03352089 - Positron Emission Tomography / Magnetic Resonance Imaging in Aortic Stenosis N/A
Recruiting NCT05814380 - The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis.
Completed NCT03923920 - Screening for Systemic Amyloidosis Via the Ligamentum Flavum
Completed NCT03886155 - Cardiac Amyloidosis Screening at Trigger Finger Release
Completed NCT03862807 - Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant Phase 3
Completed NCT02792790 - Carpal Tunnel Syndrome and Amyloid Cardiomyopathy
Completed NCT03860935 - Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy Phase 3
Recruiting NCT04963985 - The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients Phase 4
Recruiting NCT05409833 - Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population
Recruiting NCT05635045 - Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR Phase 2
Recruiting NCT03237494 - TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
Recruiting NCT04899180 - Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis Early Phase 1
Recruiting NCT06345235 - New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis
Completed NCT00628745 - Transthyretin Amyloidosis Outcome Survey (THAOS)